Durability of the Mumps Antibody Response After the Third Dose of MMR Vaccine
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiaf520 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Sun B Sowers und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, …. Hauptthemen laut MEDLINE: Measles-Mumps-Rubella Vaccine, Antibodies, Viral, Mumps, Mumps virus. Die Arbeit nennt 39 Literaturangaben. Gefördert von: CDC HHS, Marshfield Clinic Health System Foundation, Centers for Disease Control and Prevention.
Abstract (Originalsprache)
Background
A third dose of measles, mumps, and rubella vaccine (MMR3) may be administered in outbreak and nonoutbreak settings. However, data on long-term immunogenicity to the mumps component of MMR are limited. We examined durability of mumps antibody response among adults up to 11 years after receipt of MMR3.
Methods
Persons who received MMR3 at ages 18–28 years had sera collected before (baseline), 1 month, 1, 5, and 9–11 years after vaccination. Mumps antibodies were assessed by plaque reduction neutralization, immunoassay (EIA), and immunoglobulin G (IgG) avidity. Neutralizing antibodies were assessed against the vaccine strain (Genotype A) and a wild-type virus from Genotype G. Participants with neutralizing antibody titers <31 for Genotype A and <8 for Genotype G, and with EIA index values <1.10 were considered potentially susceptible.
Results
Among participants with data for all visits after MMR3 (40%, n = 262/655), susceptibility based on Genotype A titers increased from 15.7% (41/262) at baseline to 30.5% (80/262) 9–11 years after vaccination while susceptibility based on Genotype G titers remained relatively stable (30.2%–24.2%). The proportion of participants seronegative for mumps IgG by EIA increased from 0% (0/255) at baseline to 7.5% (19/255) 9–11 years after vaccination. The avidity index increased from 52% to 67% through Year 5 (P < .0001).
Conclusions
By 9–11 years after receipt of MMR3, many participants had mumps antibody levels that predicted susceptibility to infection, comparable to those observed before receipt of MMR3. The antibody titers to Genotype G remained consistently lower than the titers to the vaccine strain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
ORCID-Profile: Sun B Sowers, Huong Q Nguyen, Nina B Masters, Sara Mercader, Heather Colley, David L McClure, Carole J Hickman, Mona Marin, Stephen N Crooke
Förderung
- CDC HHS
- Marshfield Clinic Health System Foundation
- Centers for Disease Control and Prevention
Zitieren
APA
Sowers, S. B., Nguyen, H. Q., Masters, N. B., Mercader, S., Colley, H., McClure, D. L., Hickman, C. J., Marin, M., & Crooke, S. N. (2026). Durability of the Mumps Antibody Response After the Third Dose of MMR Vaccine. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf520
Vancouver
Sowers SB, Nguyen HQ, Masters NB, Mercader S, Colley H, McClure DL, et al. Durability of the Mumps Antibody Response After the Third Dose of MMR Vaccine. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf520
BibTeX
@article{Sowers2026,
author = {Sowers, Sun B and Nguyen, Huong Q and Masters, Nina B and Mercader, Sara and Colley, Heather and McClure, David L and Hickman, Carole J and Marin, Mona and Crooke, Stephen N},
title = {Durability of the Mumps Antibody Response After the Third Dose of MMR Vaccine},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiaf520}
}
EUVIMED